08:01 AM EDT, 03/26/2024 (MT Newswires) -- Optimi Health Corp. ( OPTHF ) , specializing in controlled substances such as natural psilocybin and MDMA, has entered into an international MDMA supply agreement with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV), its first venture into the Israeli market.

Optimi will supply IPR-TLV with MDMA, which was made from in-house produced active pharmaceutical ingredient (API), to support the institute's research investigating the effects of MDMA on animal models of alcohol addiction. Optimi has received the import permit from IPR-TLV and is in the process of obtaining its export permit from Health Canada.

The study is expected to start in the summer and conclude in late 2025. The outcomes of the study, including abstracts at scientific gatherings, preprints, and peer-reviewed articles, will contribute to the academic discourse surrounding the therapeutic potential of MDMA, Optimi said.